The overarching mission of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms (MPNs) is the clinical development of new and effective therapies for myeloproliferative neoplasms (MPNs); and the elucidation of the underlying biology of MPNs and leukemic transformation through translational and clinical research.
The main objectives of the Hanns A. Pielenz Clinical Research Center for MPNs are to identify and develop novel medications and strategies to effectively treat MPNs, improve the patients' quality-of-life, prolong their lives, and ultimately cure them. Our efforts are focused in three key areas:
Clinical Research in MPNs
- Conduct clinical trials with novel agents developed specifically for patients with MPNs. The Hanns A. Pielenz Clinical Research Center for MPNs provides the clinical infrastructure to conduct leading clinical research in MPNs.
Tissue Bank/Laboratory Research in MPNs
- The Hanns A. Pielenz Clinical Research Center for MPNs has established a centralized tissue bank for collection of patient samples for translational research and a database for clinical and pathology information. Our MPN tissue bank comprises specimens and clinical data (including bone marrow biopsies and mutations) for more than 2,500 patients.
Education and Awareness
- Disseminate information about MPNs and educate patients, families, and healthcare providers about the latest MPN treatments and research strategies. We periodically publish the patient-centered newsletter MPN Focus (to view the MPN Focus newsletters, please visit the side panel titled, MPN Awareness and Education) where we present all the active clinical trials, evaluating emerging MPN medications at MD Anderson, and highlight the most important findings from MPN clinical research studies.
This is a very exciting time because many new medications are being developed to treat MPNs.
Srdan Verstovsek, MD, PhD, Professor of Medicine; Director of the Hanns A. Pielenz Clinical Research Center for MPNs